It used to be that when baseball did things with its drug program, the league was accused of merely being reactive in an effort to calm down P.R. problems. If baseball had merely jacked up penalties for drug offenses — which they are reportedly doing — one might arguably say that’s what MLB was doing here, as a reaction to Biogenesis stuff. But, according to this Bob Nightengale report — from an unnamed source, so the specifics could still change — that’s not all they’re doing:
The new agreement will not only increase the drug penalties, but also implement widespread carbon isotope testing, the official said, hoping to dramatically increase the detection of a synthetic testosterone.
That’s a big deal, because the biggest problem with the Biogenesis thing wasn’t that it was somehow different or more insidious than your usual run-of-the-mill cheating, it’s that MLB didn’t catch the guys without help of an alternative newspaper in Miami. If MLB catches A-Rod on a drug test in 2012, it’s a totally different situation. Other players involved in Biogenesis may stop using. A protracted dispute about the length of penalties is not had and that arbitration from last year doesn’t exist. Toughening the testing and not letting players who use PEDs feel like they can get away with it is essential to cutting down on PED use.
But of course, increased penalties are part of the system too:
The official said first-time offenses will be 80 games, an increase from 50, and a second offense will be for an entire 162-game season instead of 100 games. There will be a lifetime suspension for a third offense.
I have no problem with this. It’s what the players want, and that’s the most important thing. It isn’t terribly draconian yet it does raise the stakes. Most importantly, there have been reports that there will be safeguards in place for players who can show that they inadvertently took a PED, so the situation that is most worrisome — a guy’s career being put at risk for an honest mistake — is off the table.
Interesting times for what many consider to be U.S. sports’ strongest drug program.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.